Mural Oncology plc MURAV 深 滬
等待開盤 07-18 09:30:00 美东时间
150.00
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 150.00
- 總市值 0
- 52周最高 150.00
- 市盈率 靜 --
- 換手率 NaN.00%
- 52周最低 0.00
- 委 比 0.00%
- 總股本 --
- 歷史最高 150.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.00
- 每 手 1
- 風險率 65.49%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Mural Oncology Shares Surge As Company Explores Strategic Alternatives: What's Going On?
Shares of Mural Oncology plc (NASDAQ: MURA) are soaring Monday following the company's announcement that it will discontinue clinical development of its lead drug candidate Nemvaleukin and begin exploring strategic alternatives.
04-16 02:09
Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges
Mural Oncology ends nemvaleukin development for ovarian cancer after ARTISTRY-7 trial misses survival goals. Phase 2 trials for melanoma continue into 2025.
03-25 21:28
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass and DUBLIN, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc ...
2024-12-04 05:16
Mural Oncology Appoints New Director and Audit Chair
Mural Oncology Plc ( ($MURA) ) has shared an announcement. Mural Oncology plc h...
2024-09-23 19:28
Mural Oncology Welcomes George Golumbeski as Director
Mural Oncology Plc (MURA) has provided an announcement. Mural Oncology plc anno...
2024-07-31 19:47
Mural Oncology plc GAAP EPS of -$3.57
Mural Oncology plc press release (NASDAQ:MURA): Q4 GAAP EPS of -$3.57. cash and cash equivalents were $270.9 million. More on Mural Oncology plc Recent Spin Mural Oncology At An Attractive Discount T...
2024-03-26 22:21
Mural Oncology Announces Enhancements to Late-Stage Clinical Trials
Strategic changes to ARTISTRY-6 and ARTISTRY-7, both potentially registrational...
2024-01-08 08:00
Why Gap Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Shares of The Gap, Inc. (NYSE: GPS) jumped in pre-market trading after the company reported better-than-expected financial results for the third quarter on Thursday.
2023-11-17 21:25
Alkermes Completes Separation of Oncology Business
— Alkermes Emerges as Pure-Play, Profitable Neuroscience Company — — Alkermes Provides Updated Financial Expectations for 2023 — DUBLIN, Nov. 15, 2023 /PRNewswire/ -- Alkermes plc (Nas...
2023-11-15 20:00
